Although the specific Lp-PLA2 inhibitor darapladib failed to reduce cardiovascular death, MI, or stroke in two large phase III trials (SOLID-TIMI and STABILITY) in patients with atherosclerosis, Lp-PLA2 might be a rational therapeutic target for ICAS with the development of more potent and selective inhibitors (6). This evidence concerns the gene PLA2G7 and Stroke.